This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
VIA AILooking for an interpreter?
Remoto by ProZ.com connects you with an identity-verified interpreter by video or phone in about 60 seconds — 300+ languages, on demand or booked ahead.
Try Remoto »
Member since Feb '13
Working languages:
Italian to Spanish English to Spanish French to Spanish Portuguese to Spanish
Access to Blue Board comments is restricted for non-members. Click the outsourcer name to view the Blue Board record and see options for gaining access to this information.
English to Spanish: Clinical trial protocol General field: Medical Detailed field: Medical (general)
Source text - English Methodology: This is a 52-week Phase 3, randomized, double-blind, parallel-group, active comparator controlled multicenter study. Subjects will be randomized in a 1:1:1 ratio to one of three treatment groups:
• Group 1: ABT-494 15 mg QD monotherapy (N = 267)
• Group 2: ABT-494 30 mg QD monotherapy (N = 267)
• Group 3: MTX monotherapy (N = 267)
Subjects who are assigned to ABT-494 15 mg QD or ABT-494 30 mg QD will start on their respective ABT-494 dose at Baseline. Subjects who are assigned to the MTX treatment group will start oral MTX treatment at 10 mg/week and will be titrated up to 20 mg/week (increase by 5 mg every 4 weeks), as tolerated.
Translation - Spanish Procedimiento: estudio de fase III, aleatorizado, con doble enmascaramiento, con grupos paralelos, multicéntrico y controlado por tratamiento activo de referencia de 52 semanas de duración. Los candidatos se asignarán aleatoriamente en proporción 1:1:1. a uno de los tres grupos de tratamiento.
• Grupo 1: monoterapia de 15 mg de ABT-494 una vez al día (N=267)
• Grupo 2: monoterapia de 30 mg de ABT-494 una vez al día (N=267)
• Grupo 3: monoterapia con MTX (N=267)
Los participantes asignados al tratamiento con 15 mg o de 30 mg de ABT-494 una vez al día empezarán con sus respectivas dosis en el periodo basal. Los participantes asignados al grupo de tratamiento con MTX empezarán el tratamiento por vía oral de 10 mg por semana y se les ajustará la dosis a 20 mg por semana (con incrementos de 5 mg cada 4 semanas), según la tolerancia.
English to Spanish: Post Implant - Precautions General field: Medical Detailed field: Medical: Instruments
Source text - English When crossing a newly deployed stent with a guide wire, balloon or delivery system, exercise care to avoid disrupting the stent geometry.
The XXXX stent has been shown in non-clinical testing to be MRI-safe immediately following implantation. MRI test conditions used to evaluate this stent were: for magnetic field interactions, a static magnetic field strength of 3 tesla with a maximumspatial gradient magnetic field of 3.3 tesla/meter; for MRI-related heating, a maximum whole body averaged specific absorption rate (SAR) of 2.0 W/kg for 15 minutes of MR imaging.
Translation - Spanish Al introducir una guía, un balón o un sistema dispensador con una endoprótesis recién desplegada, hay que tener cuidado para no alterar las características geométricas de la endoprótesis.
En estudios no clínicos se ha demostrado que es seguro realizar una resonancia magnética (RM) inmediatamente después de la implantación del sistema de endoprótesis vascular XXXX. Las condiciones de la prueba de RM aplicadas para evaluar esta endoprótesis vascular fueron: para las interacciones de campos magnéticos, una intensidad de campo magnético estático de 3 tesla con un gradiente espacial máximo del campo magnético de 3,3 tesla/metro. Para el calor causado por la RM, una tasa de absorción específica (SAR) corporal total promediada máxima de 2 W/kg durante 15 minutos de estudio de RM.
English to Spanish: Biotecnología General field: Law/Patents Detailed field: Patents
Source text - English Integration of a CRISPR spacer into the CRISPR locus of Streptococcus thermophilus provides resistance against a bacteriophage that the CRISPR spacer shows identity to. The parent DGCC7710 is phage sensitive, and the BIM DGCC7710RH2 is phage resistant. The BIM DGCC7710RH2 has a new spacer (Sn) in the CRISPR locus, which shows 100% identity to phage sequence. In step (b) the strain is challenged with phage 858 and a phage resistant mutant is selected. In step (c) The experiment was independently repeated and another mutant was selected. The CRISPR I locus of the mutant has an additional spacer (different from that in RH1) which shares 100% identity with region 17.125-17.244bp of the phage.
Translation - Spanish La integración de un espaciador CRISPR en el locus CRISPR del Streptococcus thermophilus proporciona resistencia frente un bacteriófago al que el espaciador CRISPR muestra identidad. La cepa parental DGCC7710 es sensible al fago y el BIM DGCC7710RH2 es resistente al fago. El BIM DGCC7710RH2 tiene un espaciador nuevo (Sn) en el locus CRISPR, que muestra identidad al 100 % para la secuencia de fago. En la etapa b) la cepa se estimula con el fago 858 y se selecciona un fago mutante resistente. En la etapa c) el experimento se repitió independientemente y se seleccionó otro mutante. El locus CRISPR I del mutante tiene un espaciador adicional (diferente del de RH1) que comparte identidad al 100 % con la región 17.125-17.244bp del fago.
More
Less
Translation education
Master of Specialization in Medical Translation, Master of Specialization in Patent Translation, Specialist in Immunology and Genetics in Clinical Analysis Laboratories, etc.
Experience
Years of experience: 22. Registered at ProZ.com: Feb 2013. Became a member: Feb 2013.
Medical, Pharma & Patent Translator | EN · IT · FR · PT → European Spanish
I am a Spanish medical, Life Sciences and patent translator with over 20 years of professional translation experience, working from English, French, Italian and Portuguese into Spanish (Spain).
My main areas of specialisation are medical and pharmaceutical translation, clinical trials, pharmacovigilance, medical devices and in vitro diagnostics (IVDs), biotechnology and patents. I work with specialised scientific and technical content where accuracy, terminological consistency and a thorough understanding of the subject matter are essential.
Medical & Life sciences
My professional experience covers a broad range of therapeutic areas, technologies and document types, including clinical trial documentation, pharmaceutical and pharmacovigilance content, rare diseases, medical devices, IVD and clinical laboratory systems, genetic testing, biotechnology and patient-facing medical information.
Over the years, I have worked extensively with specialised content relating to areas such as:
rare diseases, including hereditary transthyretin-mediated amyloidosis (hATTR) and neuromyelitis optica spectrum disorder (NMOSD)
multiple myeloma and AL amyloidosis
immunology and monoclonal antibody therapies
clinical genetic testing and informed consent
diabetes, HbA1c testing and blood glucose monitoring
urinalysis, diagnostic systems, reagents and clinical laboratory workflows
medical devices, healthcare equipment and associated technical and product documentation
My long-term Life Sciences experience includes a project involving approximately 100,500 words of specialised medical and pharmaceutical content in the field of hATTR amyloidosis, requiring sustained management of highly specialised disease-specific, pharmaceutical and clinical terminology.
Medical Devices & IVD
Medical devices and diagnostics are a particularly important part of my professional background. I have worked with documentation relating to a broad range of medical devices, healthcare equipment, diagnostic systems, analysers, reagents and laboratory technologies, as well as patient mobility and hospital equipment.
My practical translation experience in this field is complemented by specialised training in medical device translation, European medical device terminology and Regulation (EU) 2017/745 (MDR), including the classification and documentation of medical devices and IVDs.
Biotechnology & Patents
I also work with patent and biotechnology-related content, supported by extensive specialised training in patent translation.
My training in this area has covered biotechnology and pharmaceutical patents, patent specifications and claims, European and international patent systems, PCT procedures, patentability concepts and specialised scientific terminology, including genes and nucleic acids, siRNA, proteins, enzymes, antibodies and monoclonal antibodies, microorganisms, stem cells, biologics and genetically modified organisms.
Scientific knowledge behind the translation
I believe that high-quality medical translation requires more than linguistic competence. For this reason, I have continually developed my subject-matter knowledge through specialised training in medical translation, immunology and genetics, clinical terminology, human anatomy, pharmacology, medical devices, biotechnology, psychopathology, women's health, microbiota, metabolic health and related biomedical disciplines.
This scientific foundation allows me to approach complex source material with a deeper understanding of the concepts behind the terminology.
What I offer
My work is characterised by careful terminology research, glossary development, terminological consistency, linguistic quality assurance and close attention to scientific and technical accuracy.
Services: Translation · Editing · Proofreading · Post-editing · Terminology research and glossary development
If you are looking for a reliable Spanish linguist for specialised medical, pharmaceutical, Life Sciences, medical device, biotechnology or patent content, I would be pleased to discuss your project.
Keywords: medical translation, pharmaceutical translation, clinical trials, clinical trial protocols, medical devices, MDR, regulatory documentation, pharmacology, medical terminology, life sciences translation. See more.medical translation, pharmaceutical translation, clinical trials, clinical trial protocols, medical devices, MDR, regulatory documentation, pharmacology, medical terminology, life sciences translation, patent translation, biotech patents, pharmaceutical patents, medical device patents, technical translation, English to Spanish medical translator, Italian to Spanish medical translator, French to Spanish medical translator, Portuguese to Spanish medical translator, European Spanish, traduzione medica, traduzione farmaceutica, dispositivi medici, sperimentazioni cliniche, traduzione di brevetti, traduttore medico dall'italiano allo spagnolo, traduction médicale, traduction pharmaceutique, essais cliniques, protocoles d’essais cliniques, dispositifs médicaux, MDR, documentation réglementaire, pharmacologie, terminologie médicale, sciences de la vie, traduction de brevets, brevets biotechnologiques, brevets pharmaceutiques, brevets de dispositifs médicaux, traduction technique, traducteur médical anglais-espagnol, traducteur médical italien-espagnol, traducteur médical français-espagnol, traducteur médical portugais-espagnol, espagnol européen, tradução médica, tradução farmacêutica, ensaios clínicos, dispositivos médicos, documentação regulamentar, terminologia médica, ciências da vida, tradução de patentes, patentes farmacêuticas, patentes biotecnológicas, tradução técnica, tradutor médico de português para espanhol, espanhol europeu. See less.
This profile has received 12 visits in the last month, from a total of 12 visitors
Member since Feb '13
Blue Board entries made by this user 
